1 / 53

Gout: Its not all crystal clear

Gout: Its not all crystal clear. Robert L. Wortmann, M.D. Department of Internal Medicine The University of Oklahoma College of Medicine, Tulsa. But it should be!!!!!!!!. Name another disease that -the cause and pathophysiology are so well undeerstood

zion
Download Presentation

Gout: Its not all crystal clear

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Gout:Its not all crystal clear Robert L. Wortmann, M.D. Department of Internal Medicine The University of Oklahoma College of Medicine, Tulsa

  2. But it should be!!!!!!!! Name another disease that -the cause and pathophysiology are so well undeerstood -the diagnosis can be made with such certainty -available therapies can be so effective

  3. Objectives • Review the clinical features of gout • Review the rationale for therapies of gouty arthritis and the underlying hyperuricemia • Answer questions

  4. Clinical Features of Gout • Hyperuricemia • Acute Monoarticular Arthritis • Tophi and Chronic Arthritis • Nephrolithiasis

  5. Clinical Course of Classic Gout

  6. Stage I • Asymptomatic Hyperuricemia • Serum Urate > 7.0 mg/dl

  7. Prevalence of Hyperuricemia

  8. Factors Considered in Therapy of Asymptomatic Hyperuricemia • Renal Disease • Framingham • SMA-12 Autoanalyzer • Antihyperuricemic Medications

  9. Is Hyperuricemia a risk factor for coronary artery disease? • Hyperuricemia is a common feature of the Metabolic Syndrome • Epidemiologic studies are mixed and confusing • Richard Johnson’s rat model of hyperuricemia

  10. Management of Asymptomatic Hyperuricemia • Determine the cause • Address contributing factors • Hypertension • Obesity • Alcoholism • Hyperlipidemia • At this time, specific urate-lowering drugs are not indicated

  11. Stage II • Acute Gouty Arthritis • Intercritical Gout

  12. Clinical Course of Classic Gout

  13. Overall Gout Prevalence Among All Enrollees 1990-1999 J Rheumatol Aug 2004

  14. Annual Gout Prevalence Among All Enrollees by Age Group 1990-1999 J Rheumatol Aug 2004

  15. Therapy for Acute Gouty Arthritis • Colchicine • Oral • IV • Nonsteroidal Anti-inflammatory Agents • Corticosteroids • Intra-articular • IM (ACTH) • PO

  16. Drug Actions In Acute Gout • Colchicine inhibits • E-selectin mediated PMN adhesion • PMN L-selectin expression • Il-1 expression • Il-8 production • PMN motility • Chemotaxis

  17. Drug Actions In Acute Gout • NSAIDs • Inhibits PGE2 • Corticosteroids • Inhibit PGE2 and LTB4 • Stabilize lysosomal membranes • ACTH • Agonist of the leukocyte melatonin receptor-3

  18. The secret is not what is used, but how quickly therapy is initiated after the attack begins!

  19. Stage III • Chronic Gouty Arthritis • Tophi on physical exam • Chronic degenerative arthritis

  20. Clinical Course of Classic Gout

  21. Antihyperuricemic Therapy • Treat acute attack until resolved • Colchicine or NSAID for prophylaxis • Xanthine oxidase inhibitor or uricosuric • Address other problems • Hypertension • Obesity • Alcoholism

  22. Goal of Antihyperuricemic Therapy • Serum Urate  5.0 mg/dl! • Lowering serum urate to > 7.0 mg/dl does not reverse the problem. It only slows the rate of progression.

  23. McCarthy, Wortmann. Arthritis Rheum 1991; 34:1489.

  24. Candidates for Uricosuric Agents • Compliant patients • Under 60 years old • Good renal function* • No ASA • Can use 81 mg but sould be taken 6 hours after the uricosuric • No history of kidney stones • Underexcrete uric acid

  25. Candidates for Allopurinol • Everyone except those • Sensitive to it • Taking azathioprine • Allopurinol has • Once-a-day dosage • Few drug-drug interactions • Effective in renal failure* • Can be used in overproducers and underproducers

  26. Although there have been no new urate-lowering therapies available to treat gout since 1964, there will be soon.

  27. Urate-lowering Agents in Clinical Trials

  28. Febuxostat • A nonpurine, selective inhibitor of xanthine oxidase in phase III studies for the treatment of hyperuricemia in patients with gout • Current data support • Potent inhibition with significant urate reduction • Ability to administer in renal insufficiency1 and mild or moderate hepatic insufficiency with no dosage adjustments2 • Safe, effective and well tolerated in limited data of allopurinol intolerant patients3 CH3 OH O H3C N N N CH3 NC NH N S Allopurinol Febuxostat CO2H 1. Swan et al. Arthritis Rheum. 2003;48(9):S529. 2. Khosravan et al. Arthritis Rheum. 2004;50(9):S806. 3. Becker et al. Arthritis Rheum. 2004;50(9):S803.

  29. Febuxostat Phase III Clinical Trial • Study design: randomized, double-blind, 52 week, multicenter trial. • Objective: to assess safety and efficacy (vs. allopurinol) of daily febuxostat administration in lowering sUA levels in subjects with gout and hyperuricemia (sUA 8.0 mg/dL). • Enrollment: N=760 subjects Becker et al. ACR/ARHP Program Book Supplement. 2004;L18.

  30. Febuxostat Phase III Clinical Trial Results Compared to allopurinol, significantly more patients on either dose of febuxostat were able to achieve mean serum urate concentrations less than 6.0 mg/dL Proportion of Subjects with sUA <6.0 mg/dL (ITT Subjects) *p<0.05 for each febuxostat group vs. allopurinol group Becker et al. ACR/ARHP Program Book Supplement. 2004;L18.

  31. Why do people still suffer from gout? • Despite the fact that we understand its cause and underlying pathophysiology • Despite the fact that we can diagnosis it with absolute certainty • Despite the fact that we have such rational and effective therapies

  32. Treatment Failures • Poor prescription • Poor compliance

More Related